Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare the Vipon tampon with ibuprofen in relieving pain in women with dysmenorrhea. Subjects completed a total of 4 treatment intervals; each subject was randomized to use the VIPON as their treatment for two intervals and Ibuprofen as their treatment for two intervals.
Pain caused by dysmenorrhea can range from mild to severe. At least 50% of all menstruating women experience appreciable pain at some time during their menstruation. An estimated 600 million work hours are lost annually to this affliction with an average loss of time of two or more workdays per year per female employee. Treatment of dysmenorrhea may include either non-pharmacological or pharmacological measures. Pharmacological treatments include oral contraceptives to treat hormonal imbalances, over-the-counter analgesics or non-steroidal anti-inflammatory drugs. The Vipon is a tampon with a small motor unit within, which produces vibratory stimulation. This study aims to provide information on the safety and efficacy of the Vipon in a randomized controlled clinical trial.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Vipon | Experimental |
| |
| Ibuprofen | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vipon | Device | The Vipon is a tampon with a small motor unit within, which produces vibratory stimulation, used during menstruation to provide pain relief for women with dysmenorrhea. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Intervention Uses That Resulted in at Least 1 Point Decrease in Pain and Requiring no Rescue Medication Using the Modified Melzack-McGill Scale Using a Mixed Model | Modified Melzack-McGill Scale measures general pain (0=none, 1-3=mild, 4-6=moderate, 7-9=severe, 10=worst pain) Total Number of Uses Analyzed is a sum of the Number of Uses collected at each time point. | 1 month, 2 months, 3 months, 4 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Truman Medical Center | Kansas City | Missouri | 64108 | United States | ||
| University of Kansas Medical Center, Department of Obstetrics and Gynecology |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Vipon/Ibuprofen/Vipon/Ibuprofen | Subjects participated for a total of 4 menstrual cycles. Subjects used either VIPON as a medical device or up to 2 ibuprofen tablets (each tablet containing 200 mg ibuprofen) during the first menstrual cycle. Subjects used crossover treatment during second menstrual cycle, randomized for cycle 3, and crossed over for cycle 4. All subjects used tampons for absorption of menstrual fluid during treatment and at least 2 hours post treatment. Subjects taking ibuprofen also used a tampon during treatment. |
| FG001 | Ibuprofen/Vipon/Ibuprofen/Vipon | |
| FG002 | Vipon/Ibuprofen/Ibuprofen/Vipon | |
| FG003 | Ibuprofen/Vipon/Vipon/Ibuprofen |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Study Participants | Subjects completed a total of 4 treatment intervals; each subject was randomized to use the VIPON as their treatment for two intervals and Ibuprofen as their treatment for two intervals. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Intervention Uses That Resulted in at Least 1 Point Decrease in Pain and Requiring no Rescue Medication Using the Modified Melzack-McGill Scale Using a Mixed Model | Modified Melzack-McGill Scale measures general pain (0=none, 1-3=mild, 4-6=moderate, 7-9=severe, 10=worst pain) Total Number of Uses Analyzed is a sum of the Number of Uses collected at each time point. | Statistical analysis was carried out per plan. | Posted | Number | percentage of uses | 1 month, 2 months, 3 months, 4 months | uses of intervention | Participants |
|
Not provided
No Serious Adverse Events were deemed to be related to the VIPON.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Study Participants | Subjects completed a total of 4 treatment intervals; each subject was randomized to use the VIPON as their treatment for two intervals and Ibuprofen as their treatment for two intervals. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pregnancy | Reproductive system and breast disorders | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Acne | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Charles Tepper | Another Way Products | 917-538-6894 | charles_tepper@yahoo.com |
Not provided
| ID | Term |
|---|---|
| D004412 | Dysmenorrhea |
| ID | Term |
|---|---|
| D008599 | Menstruation Disturbances |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D017699 | Pelvic Pain |
Not provided
Not provided
| ID | Term |
|---|---|
| D007052 | Ibuprofen |
| D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| ID | Term |
|---|---|
| D010666 | Phenylpropionates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Ibuprofen | Drug | 400 mg daily |
|
|
| Kansas City |
| Missouri |
| 66160 |
| United States |
| Participants |
|
| Age Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Ibuprofen |
Subjects completed 4 treatment intervals; each subject was randomized to use the VIPON as their treatment during two intervals and Ibuprofen as their treatment during two intervals. |
|
|
|
| 2 |
| 102 |
| 48 |
| 102 |
| Appendicitis | Gastrointestinal disorders | Non-systematic Assessment |
|
| Anemia | Blood and lymphatic system disorders | Non-systematic Assessment |
|
| Anxiety | Psychiatric disorders | Non-systematic Assessment |
|
| Back ache | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
|
| Bronchitis | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
|
| Cellulitis | Infections and infestations | Non-systematic Assessment |
|
| Chest congestion | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
|
| Chest pain | General disorders | Non-systematic Assessment |
|
| Chills | General disorders | Non-systematic Assessment |
|
| Cold | General disorders | Non-systematic Assessment |
|
| Colposcopy | Reproductive system and breast disorders | Non-systematic Assessment |
|
| Cough | General disorders | Non-systematic Assessment |
|
| Cramps | Reproductive system and breast disorders | Non-systematic Assessment |
|
| Cryptosporidiosis | Infections and infestations | Non-systematic Assessment |
|
| Daytime hypersomnia | General disorders | Non-systematic Assessment |
|
| Decreased appetite | General disorders | Non-systematic Assessment |
|
| Dental abscess | General disorders | Non-systematic Assessment |
|
| Dental infection | Infections and infestations | Non-systematic Assessment |
|
| Dental pain | General disorders | Non-systematic Assessment |
|
| Depression | Psychiatric disorders | Non-systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | Non-systematic Assessment |
|
| Elevated blood pressure | Cardiac disorders | Non-systematic Assessment |
|
| Fatigue | General disorders | Non-systematic Assessment |
|
| Generalized body aches | General disorders | Non-systematic Assessment |
|
| Giardia | Infections and infestations | Non-systematic Assessment |
|
| Headache | General disorders | Non-systematic Assessment | A single device-related adverse event, headache, occurred during the study and the relationship to the device was deemed "possible". |
|
| Hypercholesterolemia | General disorders | Non-systematic Assessment |
|
| Hypertension | Cardiac disorders | Non-systematic Assessment |
|
| Insect bite | General disorders | Non-systematic Assessment |
|
| Joint swelling | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
|
| Lymphedema | Immune system disorders | Non-systematic Assessment |
|
| Menorrhagia | Reproductive system and breast disorders | Non-systematic Assessment |
|
| Mountain sickness | General disorders | Non-systematic Assessment |
|
| Neck pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
|
| Pericarditis | Cardiac disorders | Non-systematic Assessment |
|
| Peridontal surgery | Surgical and medical procedures | Non-systematic Assessment |
|
| Poison ivy reaction | Infections and infestations | Non-systematic Assessment |
|
| Rash | Infections and infestations | Non-systematic Assessment |
|
| Rectal bleeding | Gastrointestinal disorders | Non-systematic Assessment |
|
| Respiratory infection | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
|
| Achilles tendon pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
|
| Ankle pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
|
| Knee pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
|
| Labial biopsy | Surgical and medical procedures | Non-systematic Assessment |
|
| Root canal | General disorders | Non-systematic Assessment |
|
| Cyst | Infections and infestations | Non-systematic Assessment |
|
| Shoulder pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
|
| Sinus infection | Infections and infestations | Non-systematic Assessment |
|
| Stomach flu | General disorders | Non-systematic Assessment |
|
| Stomach pain | Gastrointestinal disorders | Non-systematic Assessment |
|
| Strep throat | Infections and infestations | Non-systematic Assessment |
|
| Sunburn | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
|
| Swollen bruised right eye | General disorders | Non-systematic Assessment |
|
| Tick bite | General disorders | Non-systematic Assessment |
|
| Twisted back | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
|
| Upper respiratory infection | Infections and infestations | Non-systematic Assessment |
|
| Urinary tract infection | Infections and infestations | Non-systematic Assessment |
|
| Vaginal yeast infection | Infections and infestations | Non-systematic Assessment |
|
The PI agrees not to originate or use the name of Another Way Products, LLC and/or VIPON, or any of its employees, in any publicity, news release or other public announcement, written or oral, whether to the public, press or otherwise, relating to this protocol, to any amendment herto, or to the performance here under, without the prior written consent of Another Way Products, LLC
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D018712 |
| Analgesics, Non-Narcotic |
| D000700 | Analgesics |
| D018689 | Sensory System Agents |
| D018373 | Peripheral Nervous System Agents |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D000893 | Anti-Inflammatory Agents |
| D045506 | Therapeutic Uses |
| D018501 | Antirheumatic Agents |